Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Organon & Co.

< Previous 1 2 3 Next >
Organon To Report Third Quarter Results and Host Conference Call on November 3, 2022
From Organon & Co.
Via Business Wire
Tickers OGN
Samsung Bioepis and Organon Announce FDA Approval of Citrate-Free High-Concentration HUMIRA® Biosimilar HADLIMA™ (adalimumab-bwwd)
From Organon & Co.
Via Business Wire
Tickers OGN
Organon Reports Results for the Second Quarter Ended June 30, 2022
From Organon & Co.
Via Business Wire
Tickers OGN
Organon and Cirqle Biomedical Enter Research Collaboration and License Agreement for Investigational Non-hormonal, On-demand Contraceptive Candidate
From Organon & Co.
Via Business Wire
Tickers OGN
Organon To Report Second Quarter Results and Host Conference Call on August 4, 2022
From Organon & Co.
Via Business Wire
Tickers OGN
Organon Enters into Global License Agreement to Commercialize Henlius’ Investigational Perjeta® (Pertuzumab) and Prolia®/Xgeva® (Denosumab) Biosimilar Candidates
From Organon & Co.
Via Business Wire
Tickers OGN
On One Year Anniversary, Organon Introduces Global ESG Strategy and Commitments with Publication of Inaugural ESG Report
From Organon & Co.
Via Business Wire
Tickers OGN
Organon Reports Results for the First Quarter Ended March 31, 2022
From Organon & Co.
Via Business Wire
Tickers OGN
Organon To Report First Quarter Results and Host Conference Call on May 5, 2022
From Organon & Co.
Via Business Wire
Tickers OGN
Organon Enters into Global License Agreement to Commercialize Daré Bioscience’s XACIATO™ (clindamycin phosphate vaginal gel, 2%), FDA-Approved Treatment for Females 12 and Older with Bacterial Vaginosis (BV)
From Organon & Co.
Via Business Wire
Tickers DARE OGN
Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2021
From Organon & Co.
Via Business Wire
Tickers OGN
Organon Acquires Contraceptive Products, Marvelon® and Mercilon®, in the People’s Republic of China, including Hong Kong and Macau, and Agrees to Acquire these Products in Vietnam
From Organon & Co.
Via Business Wire
Tickers OGN
Organon Declares Paid Time Off for All Employees on International Women’s Day; Employees to Focus on Their Own Health in Recognition of Growing Women’s Health Inequity
From Organon & Co.
Via Business Wire
Tickers OGN
Organon To Report Fourth Quarter and Full Year Results and Host Conference Call on February 17, 2022
From Organon & Co.
Via Business Wire
Tickers OGN
FDA Accepts Samsung Bioepis’ and Organon’s sBLA for their Citrate-Free, High-Concentration HUMIRA® (Adalimumab) Biosimilar Candidate
From Organon & Co.
Via Business Wire
Tickers OGN
Organon To Present at the 40th Annual J.P. Morgan Healthcare Virtual Conference
From Organon & Co.
Via Business Wire
Tickers OGN
Organon Completes Acquisition of Forendo Pharma
From Organon & Co.
Via Business Wire
Tickers OGN
Organon To Present at the Evercore ISI 4th Annual HealthCONx Conference
From Organon & Co.
Via Business Wire
Tickers OGN
Organon Reports Results for the Third Quarter Ended September 30, 2021
From Organon & Co.
Via Business Wire
Tickers OGN
Organon to Acquire Forendo Pharma
From Organon & Co.
Via Business Wire
Tickers OGN
Organon To Report Third Quarter Results and Host Conference Call on November 11, 2021
From Organon & Co.
Via Business Wire
Tickers OGN
Organon Launches New Fertility Journey Website as Part of Ongoing Commitment to Help Address the Needs of Women
From Organon & Co.
Via Business Wire
Tickers OGN
Organon Receives FDA Clearance for Technological Updates to the Jada® System, a Medical Device Intended to Control Postpartum Hemorrhage
From Organon & Co.
Via Business Wire
Tickers OGN
Organon Aims to Ignite Worldwide Conversation Around Unplanned Pregnancy
From Organon & Co.
Via Business Wire
Tickers OGN
Organon To Present at Morgan Stanley’s 19th Annual Global Healthcare Virtual Conference
From Organon & Co.
Via Business Wire
Tickers OGN
Organon To Present at Citi’s 16th Annual BioPharma Virtual Conference
From Organon & Co.
Via Business Wire
Tickers OGN
Organon Reports Results for the Second Quarter Ended June 30, 2021 and Announces Inaugural Dividend
From Organon & Co.
Via Business Wire
Tickers OGN
Organon To Report Fiscal Q2 Results and Host Conference Call on August 12, 2021
From Organon & Co.
Via Business Wire
Tickers OGN
Organon Recommends Stockholders Reject Below-Market Mini-Tender Offer by TRC Capital Investment Corporation
From Organon & Co.
Via Business Wire
Tickers OGN
Organon Announces Filing of Form 10-Q for the Quarter Ended March 31, 2021
From Organon & Co.
Via Business Wire
Tickers OGN
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.